• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

K252a通过阻断血小板衍生生长因子信号转导来抑制胶质瘤细胞的增殖。

K252a inhibits proliferation of glioma cells by blocking platelet-derived growth factor signal transduction.

作者信息

Chin L S, Murray S F, Zitnay K M, Rami B

机构信息

Department of Neurosurgery, Program in Oncology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.

出版信息

Clin Cancer Res. 1997 May;3(5):771-6.

PMID:9815748
Abstract

Growth factors are known to regulate glioma proliferation. The glioma cell lines U87 and T98G were examined for evidence of an autocrine stimulatory loop involving the neurotrophin family of growth factors. Although neurotrophin-3 and TrkC RNA were detected by reverse transcription-PCR, there was no evidence of significant interaction between neurotrophin-3 and its cognate receptor TrkC. The microbial alkaloid K252a has been described to inhibit both Trk tyrosine kinase activity and neuroblastoma cell proliferation. K252a inhibited proliferation in U87 (IC50 = 1170 nM) and T98G (IC50 = 529 nM) but induced apoptosis in U87 cells only. At concentrations of 500 nM to 1 microM, K252a blocked only platelet-derived growth factor (PDGF)-mediated receptor autophosphorylation. These results suggest that an autocrine loop involving PDGF is functional and important for maintaining tumor growth. There is no evidence to support the existence of a neurotrophin-mediated autocrine loop. K252a, through inhibition of PDGF signal transduction, may be a novel therapeutic agent in the treatment of human gliomas.

摘要

已知生长因子可调节胶质瘤的增殖。对胶质瘤细胞系U87和T98G进行了检测,以寻找涉及神经营养因子家族生长因子的自分泌刺激环的证据。尽管通过逆转录聚合酶链反应检测到了神经营养因子-3和TrkC RNA,但没有证据表明神经营养因子-3与其同源受体TrkC之间存在显著相互作用。微生物生物碱K252a已被描述为可抑制Trk酪氨酸激酶活性和成神经细胞瘤细胞增殖。K252a抑制U87(IC50 = 1170 nM)和T98G(IC50 = 529 nM)的增殖,但仅诱导U87细胞凋亡。在500 nM至1 microM的浓度下,K252a仅阻断血小板衍生生长因子(PDGF)介导的受体自磷酸化。这些结果表明,涉及PDGF的自分泌环对于维持肿瘤生长具有功能性且很重要。没有证据支持神经营养因子介导的自分泌环的存在。K252a通过抑制PDGF信号转导,可能是治疗人类胶质瘤的一种新型治疗药物。

相似文献

1
K252a inhibits proliferation of glioma cells by blocking platelet-derived growth factor signal transduction.K252a通过阻断血小板衍生生长因子信号转导来抑制胶质瘤细胞的增殖。
Clin Cancer Res. 1997 May;3(5):771-6.
2
Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.N-[4-(三氟甲基)-苯基]5-甲基异恶唑-4-甲酰胺对血小板衍生生长因子介导的信号转导及肿瘤生长的抑制作用
Clin Cancer Res. 1997 Jul;3(7):1167-77.
3
K252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors.K252a是一种原癌基因trk家族和神经营养因子受体酪氨酸蛋白激酶活性的选择性抑制剂。
Oncogene. 1992 Feb;7(2):371-81.
4
An abnormal response of retinoblastoma cells (Y-79) to neurotrophins.视网膜母细胞瘤细胞(Y-79)对神经营养因子的异常反应。
Invest Ophthalmol Vis Sci. 2000 Jun;41(7):1932-9.
5
Anti-proliferative effect of the kinase inhibitor K252a on human prostatic carcinoma cell lines.激酶抑制剂K252a对人前列腺癌细胞系的抗增殖作用。
J Androl. 1996 Sep-Oct;17(5):481-90.
6
Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells.槲皮素和木犀草素对表皮生长因子受体酪氨酸激酶活性的阻断导致胰腺肿瘤细胞的生长抑制和凋亡。
Anticancer Res. 2002 May-Jun;22(3):1615-27.
7
Neurotrophic factors in the human cornea.人类角膜中的神经营养因子。
Invest Ophthalmol Vis Sci. 2000 Mar;41(3):692-702.
8
Platelet-derived growth factor in human glioma.人胶质瘤中的血小板衍生生长因子
Glia. 1995 Nov;15(3):257-63. doi: 10.1002/glia.440150307.
9
Effect of exogenous neurotrophins on Trk receptor phosphorylation, cell proliferation, and neurotrophin secretion by cells isolated from the human lamina cribrosa.外源性神经营养因子对从人筛板分离出的细胞的Trk受体磷酸化、细胞增殖及神经营养因子分泌的影响
Mol Vis. 2004 Apr 19;10:289-96.
10
Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.伊马替尼在恶性胶质瘤细胞中的差异效应及与化疗药物联合治疗的协同作用
Basic Clin Pharmacol Toxicol. 2009 Mar;104(3):241-52. doi: 10.1111/j.1742-7843.2008.00371.x. Epub 2009 Jan 21.

引用本文的文献

1
Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.伊马替尼治疗各种组织学类型复发性神经胶质瘤患者的II期研究:欧洲癌症研究与治疗组织脑肿瘤研究组的一项研究
J Clin Oncol. 2008 Oct 1;26(28):4659-65. doi: 10.1200/JCO.2008.16.9235.